Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Medivation Announces First Presentation of Dimebon(TM) Behavioral and Caregiver Impact Data at Annual Meeting of American Association for Geriatric Psychiatry
March 28th, 2008
Medivation, Inc. (NASDAQ:MDVN) announced that subdomain data on the effect of Dimebon(TM) on behavioral symptoms in patients with mild-to-moderate Alzheimer's disease and the impact on caregivers will be presented for the first time at the annual meeting of the American Association for Geriatric Psychiatry (AAGP) in Orlando. The data, from the Company's first pivotal trial of Dimebon, will be presented by Jeffrey Cummings, M.D., on Saturday, March 15, at 1:00 p.m. Eastern time during a poster session on new research topics. The poster presentation is entitled "Dimebon Stabilizes Neuropsychiatric Symptoms in Alzheimer's Disease: One-year Clinical Trial Results." ...
Source: Health Business Week (2008-03-28)
|
